 A PHASE 2 CLINICAL STUDY IN SUBJECTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF TWO ORAL DOSES OF LAQUINIMOD EITHER OF 0.6 MGDAY OR 1.5MGDAY EXPERIMENTAL DRUG AS COMPARED TO PLACEBO: 